We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

6 hedge funds and large institutions have $7.22K invested in ZyVersa Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding

Funds holding: 4 → 6 (+2)

0.94% less ownership

Funds ownership: 1.23% → 0.29% (-0.94%)

81% less capital invested

Capital invested by funds: $38.7K → $7.22K (-$31.5K)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$5.99K
2
UBS Group
UBS Group
Switzerland
+$1.39K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$167
4
Bank of America
Bank of America
North Carolina
+$3
5
Morgan Stanley
Morgan Stanley
New York
+$3

Top Sellers

Rank Fund Capital Flow
1
ACM
ADAR1 Capital Management
Texas
-$36.1K

ZVSA Hedge Fund Activity: Q3 2024 in Review

6 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q3 2024, worth a combined $7.22K — down 81% from $38.7K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ZVSA positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $5.99K. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $36.1K sold.

  • 6 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q3 2024, up from 4 in Q2 2024.
  • Funds reported $7.22K of ZyVersa Therapeutics stock for Q3 2024, down 81% quarter-over-quarter.
  • 3 funds opened new ZyVersa Therapeutics positions in Q3 2024 and 1 closed out, a net change of +2 holders.
  • The largest ZyVersa Therapeutics buyer in Q3 2024 was Tower Research Capital (TRC), an estimated $5.99K added.
  • The largest ZyVersa Therapeutics seller in Q3 2024 was ADAR1 Capital Management, an estimated $36.1K sold.

Based on aggregated 13F filings for Q3 2024.